Joseph Vallner Joins Lumera's Board; Adds Industry Leadership and Expertise in Bioscience Field

Dr. Vallner joined Cell Genesys in October 1999 and serves asPresident and Chief Operating Officer. He currently oversees theresearch, development, manufacturing, clinical, regulatory andoperations departments. Prior to Cell Genesys, he was with SEQUUSPharmaceuticals for seven years where he was instrumental in thelaunch of two products including Doxil(R), a liposome-based cancertherapeutic. He also helped transition the company through its mergerwith ALZA Corporation. Prior to SEQUUS, he held various positions withSyntex Corporation and G.D. Searle and Company. Prior to his corporateexperience, Dr. Vallner was an associate professor of pharmaceutics atthe University of Georgia. He serves as a board member of theCalifornia Healthcare Institute. Dr. Vallner received his Ph.D. inpharmaceutics, an M.S. in physical chemistry and a B.S. in pharmacyfrom the University of Wisconsin, Madison.

"We are delighted to have someone of Joe's caliber and experiencejoin the Lumera board," said Tom Mino, President and Chief ExecutiveOfficer. "His operational expertise in bioscience will help us toincrease productivity as we grow our proteomics business."

About Lumera

Lumera is a leader in the emerging field of nanotechnology. Thecompany designs proprietary molecular structures and polymer compoundsfor the bioscience and communications/computing industries, both ofwhich represent large market opportunities. The company also hasdeveloped proprietary processes for fabricating such devices. For moreinformation, please visit www.lumera.com.

Certain statements contained in this release are forward-lookingstatements that involve a number of risks and uncertainties. Factorsthat could cause actual results to differ materially from thoseprojected in the company's forward-looking statements include thefollowing: market acceptance of our technologies and products; ourability to obtain financing; our financial and technical resourcesrelative to those of our competitors; our ability to keep up withrapid technological change; government regulation of our technologies;our ability to enforce our intellectual property rights and protectour proprietary technologies; the ability to obtain additionalcontract awards and to develop partnership opportunities; the timingof commercial product launches; the ability to achieve key technicalmilestones in key products; and other risk factors identified fromtime to time in the company's SEC reports, including its Annual Reporton Form 10-K, and its Quarterly Reports on Form 10-Q.